second-line chemotherapy

second-line chemotherapy

Oncology Any chemotherapeutic administered after the agent of choice fails
References in periodicals archive ?
The second-line chemotherapy options include pemetrexed (if not administered first line), vinorelbine, or gemcitabine.
Recurrence of Hodgkin lymphoma occurs in almost half of patients following autologous stem cell transplantation, and the prognosis for patients relapsing or refractory to second-line chemotherapy and transplant is particularly poor, which means there is a significant need to identify therapeutic options that provide meaningful clinical benefit, said Dr.
One (14%) patient showed persistent disease activity on biopsy and he was treated with second-line chemotherapy but ultimately progressed and died.
The colorectal cancer therapeutics market in APAC is segmented based on lines of chemotherapy: first-line chemotherapy and second-line chemotherapy.
With a poorly differentiated carcinoma spread all over the skeletal system, gut, abdomen, and pelvis, the patient tolerated the second-line chemotherapy also and is still surviving 2 years after the detection of CUP.
In the ITT population, 91 patients received a first-line and 48 patients received a second-line chemotherapy or higher; 89 patients were treated with a TX, 45 patients with a GX, and 5 patients with an NX combination chemotherapy.
But many patients relapse and go on to get an autologous stem cell transplant after second-line chemotherapy.
As both liposomal doxorubicin and the taxane drugs are not available in the public healthcare sector, second-line chemotherapy could not be offered.
Study participants either had relapsed, did not respond to second-line chemotherapy or had relapsed following hematopoietic stem cell transplantation.
The company's AFFINITY trial will evaluate if custirsen when combined with second-line chemotherapy has the potential to improve survival outcomes for prostate cancer patients compared to second-line chemotherapy alone.
Written for clinicians, nurses, researchers, medical students, residents, and fellows, the text opens with an update on prostate cancer prevention followed by chapters covering screening, current surgical approaches to primary prostate cancer treatment, updates on radiation dose escalation, androgen-deprivation therapy (ADT) for advanced prostate cancer, novel androgen receptor therapeutic targets for advanced prostate cancer, metabolic complications of ADT, docetaxel-based chemotherapy in castration-resistant prostate cancer (CRPC), second-line chemotherapy for CRPC, emerging role of immunotherapy in prostate cancer treatment, novel bone-targeted therapy in metastatic CRPC (mCRPC), and emerging treatment strategies for mCRPC.